Details for Patent: 5,766,573

United States Drug Patent 5,766,573: Scope, Claims, and Landscape Analysis

United States Patent 5,766,573, titled "Substituted pyrazolo[1,5-a]pyrimidin-7-ones," was granted to Pfizer Inc. on June 16, 1998. The patent covers a class of chemical compounds exhibiting activity against kinase enzymes, particularly phosphodiesterase type 4 (PDE4). These compounds are indicated for the treatment of inflammatory conditions, including asthma and chronic obstructive pulmonary disease (COPD).

What is the Core Technology Claimed in Patent 5,766,573?

The patent claims a class of substituted pyrazolo[1,5-a]pyrimidin-7-ones. The general structure is defined by a core bicyclic ring system with specific substituents at various positions. The patent details the preparation of these compounds and provides data demonstrating their biological activity.

• Compound Structure: The claims encompass a broad genus of compounds with the following general formula:

  [Structure of the pyrazolo[1,5-a]pyrimidin-7-one core with defined substituent positions. Specific substituents and their allowed variations are detailed in the patent text.]

  The patent explicitly defines the R1, R2, and R3 substituents, along with variations on the pyrazolo[1,5-a]pyrimidin-7-one core. These variations include, but are not limited to, specific heterocyclic and aromatic groups, halogens, and alkyl chains.

• Biological Activity: The primary asserted biological activity is the inhibition of phosphodiesterase type 4 (PDE4). PDE4 enzymes are involved in the regulation of intracellular cyclic adenosine monophosphate (cAMP) levels, which play a crucial role in inflammatory processes. Inhibition of PDE4 leads to increased cAMP, which can suppress the release of inflammatory mediators from cells such as neutrophils, eosinophils, and macrophages.

• Therapeutic Indications: The compounds are claimed for use in treating inflammatory conditions. Specifically mentioned indications include:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Inflammatory skin diseases (e.g., psoriasis, atopic dermatitis)
  • Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

What are the Specific Claims within Patent 5,766,573?

The patent comprises multiple claims, ranging from the specific chemical compounds to their methods of use.

Claim 1: The Core Chemical Composition

Claim 1 is the broadest independent claim, defining the central chemical genus. It specifies a compound of the formula:

[Formula as defined in Claim 1 of U.S. Patent 5,766,573, detailing the substituents R1, R2, R3 and allowable variations.]

This claim requires the presence of specific groups at positions R1, R2, and R3, where R1 is an optionally substituted aryl or heteroaryl group, R2 is hydrogen or an alkyl group, and R3 is an optionally substituted aryl, heteroaryl, or cyclic aliphatic group. The patent meticulously defines the allowable substituents and their positions.

Other Independent and Dependent Claims

• Claim 2: A specific subclass of compounds where R1 is a substituted phenyl ring, further refining the scope of Claim 1.
• Claim 3: Further defines R3 as a specific type of heterocyclic ring system.
• Claim 4: A pharmaceutical composition containing at least one compound of Claim 1 and a pharmaceutically acceptable carrier.
• Claim 5: A method of treating an inflammatory condition in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of Claim 1.
• Claims 6-15: Dependent claims that further narrow the scope of the independent claims by specifying particular substituents and their configurations. For instance, they might detail specific phenyl substituents (e.g., methoxy, halogen) or specific heterocyclic ring systems for R3.

The claims are structured to capture a broad chemical space while allowing for specific embodiments that have been synthesized and tested.

How does Patent 5,766,573 Relate to Known PDE4 Inhibitors?

Patent 5,766,573 belongs to a broader class of phosphodiesterase type 4 (PDE4) inhibitors. The development of PDE4 inhibitors has been an active area of pharmaceutical research due to the role of PDE4 in inflammatory pathways.

• Roflumilast (Daliresp/Daxas): This drug, developed by Merck, is a selective PDE4 inhibitor approved for severe COPD. While roflumilast has a different core chemical structure (a benzamide derivative), it targets the same enzyme. The development of roflumilast occurred in parallel with research into other PDE4 inhibitor classes, including those potentially encompassed by patents like 5,766,573.
• Apremilast (Otezla): Another PDE4 inhibitor, apremilast (Amgen/Celgene), is approved for psoriasis and psoriatic arthritis. Apremilast's chemical structure is distinct from the pyrazolo[1,5-a]pyrimidin-7-ones.
• Pfizer's Research: Pfizer has historically invested in PDE4 inhibitor research. Compounds within the scope of 5,766,573 may have been part of their pipeline or served as leads for further optimization, potentially leading to other proprietary compounds or drugs.

The patent's significance lies in its contribution to the intellectual property surrounding the pyrazolo[1,5-a]pyrimidin-7-one scaffold for PDE4 inhibition, a mechanism that has proven therapeutically valuable.

What is the Patent Landscape for Pyrazolo[1,5-a]pyrimidin-7-one PDE4 Inhibitors?

The patent landscape for pyrazolo[1,5-a]pyrimidin-7-one PDE4 inhibitors is characterized by extensive patent filings by major pharmaceutical companies, reflecting the therapeutic potential of this chemical class.

Key Players and Patent Filings

• Pfizer Inc.: As the assignee of 5,766,573, Pfizer holds foundational intellectual property in this specific subclass.
• Other Major Pharmaceutical Companies: Companies such as GlaxoSmithKline, Novartis, Merck & Co., and others have also filed numerous patents covering various pyrazolo[1,5-a]pyrimidin-7-one derivatives and their therapeutic applications for inflammatory diseases. These filings often explore different substituent patterns and novel synthetic routes.
• Academic Institutions: Universities and research institutions also contribute to the patent literature, often by identifying novel scaffolds or biological targets.

Patent Filing Trends

• Early Filings (1990s-Early 2000s): This period saw significant foundational patenting activity for PDE4 inhibitors, including the class claimed in 5,766,573. Companies aimed to secure broad coverage for promising chemical series.
• Subsequent Filings (Mid-2000s onwards): Later filings tend to focus on more specific compound improvements, novel formulations, combination therapies, and new therapeutic indications for PDE4 inhibitors. Patent thickets can emerge around successful drug candidates, with companies filing patents on variations, polymorphs, and manufacturing processes to extend market exclusivity.

Patent Expiration and Generic Competition

Patent 5,766,573, granted in 1998, has an expiration date based on its grant date and its filing date. Assuming a standard patent term, its effective patent term has likely expired or is nearing expiration.

• Expiration Date Calculation: U.S. Patent term is generally 20 years from the application filing date, plus potential extensions (e.g., Patent Term Adjustment). For a patent filed in the mid-1990s and granted in 1998, the core patent term would have concluded in the late 2010s.
• Impact on Generic Entry: As the primary patent term expires, the market becomes more open to generic competition, provided no other patents (e.g., on specific formulations, manufacturing processes, or new uses) remain in force.

Freedom to Operate (FTO) Considerations

Companies seeking to develop new PDE4 inhibitors, particularly those with a pyrazolo[1,5-a]pyrimidin-7-one core, must conduct thorough freedom-to-operate analyses. This involves identifying all relevant active patents, including those that may have been filed subsequent to 5,766,573, and assessing potential infringement risks. The existence of a complex patent landscape necessitates careful navigation to avoid infringing on existing intellectual property rights.

What are the Manufacturing and Synthetic Considerations for Compounds Under 5,766,573?

The synthesis of pyrazolo[1,5-a]pyrimidin-7-one derivatives involves multi-step organic chemistry procedures. The patent itself details specific synthetic routes for example compounds.

Key Synthetic Pathways

The general synthetic approach typically involves the condensation of a suitably substituted pyrazole with a beta-keto ester or a related functionalized three-carbon unit.

1. Pyrazole Synthesis: This often begins with commercially available hydrazines or dicarbonyl compounds, followed by cyclization.
2. Condensation and Cyclization: The pyrazole is then reacted with a beta-keto ester (e.g., ethyl acetoacetate derivatives) or similar synthons under acidic or basic conditions to form the pyrazolo[1,5-a]pyrimidin-7-one core.
3. Functional Group Modification: Subsequent steps involve introducing or modifying the substituents (R1, R2, R3) on the core structure. This can include alkylation, acylation, halogenation, Suzuki couplings, or other cross-coupling reactions to attach aryl or heteroaryl groups.

Challenges in Scale-Up and Manufacturing

• Regioselectivity: Ensuring the correct regiochemistry during condensation and substitution reactions can be challenging and may require specific catalysts or reaction conditions.
• Yield Optimization: Achieving high yields across multiple synthetic steps is critical for cost-effective manufacturing.
• Purification: Complex mixtures can arise, necessitating efficient chromatographic or crystallization methods for isolating pure target compounds.
• Stereochemistry: If chiral centers are present in the substituents, controlling stereochemistry adds another layer of complexity to the synthesis and purification.
• Impurity Profiling: Identifying and controlling process-related impurities is essential for pharmaceutical development and regulatory approval.

Key Takeaways

• U.S. Patent 5,766,573 by Pfizer Inc. covers a broad class of substituted pyrazolo[1,5-a]pyrimidin-7-ones, primarily for their activity as PDE4 inhibitors.
• The patent claims specific chemical structures and their use in treating inflammatory diseases like asthma and COPD.
• The core technology is the pyrazolo[1,5-a]pyrimidin-7-one scaffold, a chemical entity that has been extensively investigated for PDE4 inhibition.
• The patent landscape for this class of compounds is characterized by numerous filings from various pharmaceutical entities, creating a complex intellectual property environment.
• The patent term for 5,766,573 has likely expired, opening avenues for potential generic development, contingent on the absence of other active patents.
• Synthetic routes for these compounds involve multi-step organic chemistry, with potential challenges in regioselectivity, yield optimization, and purification for large-scale manufacturing.

Frequently Asked Questions

1. What is the primary therapeutic target of the compounds claimed in Patent 5,766,573? The primary therapeutic target is phosphodiesterase type 4 (PDE4).

2. Has any drug based on the specific chemical structure of Patent 5,766,573 reached the market? Information publicly available does not indicate a drug directly based on the core structure of U.S. Patent 5,766,573 has reached the market under that specific patent. However, the scaffold and mechanism remain relevant.

3. When did Patent 5,766,573 likely expire, allowing for generic development? Given its grant date of June 16, 1998, the primary patent term likely expired in the late 2010s.

4. What are the key inflammatory conditions for which these compounds are claimed to be effective? The patent claims effectiveness for asthma, COPD, and inflammatory skin and bowel diseases.

5. Beyond Pfizer, which other entities are active in the patent landscape for pyrazolo[1,5-a]pyrimidin-7-one PDE4 inhibitors? Major pharmaceutical companies including GlaxoSmithKline, Novartis, and Merck & Co. are also active in this patent space.

Citations

[1] Pfizer Inc. (1998). U.S. Patent 5,766,573: Substituted pyrazolo[1,5-a]pyrimidin-7-ones. United States Patent Office.